LUTREPULSE KIT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUTREPULSE KIT is a small-molecule injectable formulation approved in 1989 for hormone-related indications. The product utilizes a pulsatile delivery mechanism to replicate physiologic hormone patterns. Mechanism of action and specific indications are not publicly detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling transition planning and potential team restructuring ahead.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching status indicate minimal hiring and career growth on this product. Professionals on LUTREPULSE teams should plan transition strategies to growth-stage or newer pipeline assets within Ferring.
Brand ManagerSales Representative
Worked on LUTREPULSE KIT at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.